PFE
Pfizer Inc
27.70$
+0.3%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +8.0% | +2.1% | -10.7% | +33.3% | +0.3% | -22.8% | +6.8% | +13.7% | +5.4% | -17.7% | +4.0% | – | |
| – | -19.0% | -49.0% | +15.0% | +37.5% | -30.8% | -18.9% | +34.6% | -20.3% | +26.4% | -10.3% | -13.5% | – | |
| – | +107.1% | +75.6% | -21.5% | +30.7% | +20.4% | -24.2% | -4.1% | +32.5% | -1.6% | -20.9% | +12.6% | – | |
| – | +3.4% | -10.6% | +7.9% | -4.1% | +17.6% | -27.8% | +12.1% | +61.1% | -13.2% | -23.1% | +6.9% | – | |
| – | -76.9% | +349.8% | +6.4% | -12.7% | -55.7% | +110.9% | +12.7% | -6.7% | +28.1% | -27.4% | +15.2% | – | |
| – | +22.9% | -18.0% | +7.2% | -8.8% | +24.8% | -28.2% | +12.3% | +52.8% | -3.8% | -33.8% | +9.6% | – | |
| – | – | – | -58.8% | +164.4% | +15.2% | -19.2% | -22.7% | -0.7% | +3.9% | +9.3% | +16.7% | – | |
| – | -0.9% | +14.7% | -1.5% | +0.6% | -5.6% | -11.5% | +0.0% | -0.3% | +9.0% | -6.0% | -0.1% | – | |
| – | – | – | -103.0% | – | -100.2% | – | +9.3% | +9.5% | -149.3% | – | -120.6% | – | |
| – | – | – | -145.7% | – | -279.9% | – | – | -253.2% | – | – | -188.3% | – | |
| – | – | – | -99.2% | +18,537.5% | -91.0% | +636.2% | -1.9% | +21.7% | -146.5% | – | -109.2% | – | |
| – | – | – | -59.6% | +201.6% | -29.1% | -1.7% | +5.3% | +6.1% | -86.6% | +564.2% | -76.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.